08:26 AM EDT, 03/19/2024 (MT Newswires) -- Revive Therapeutics Ltd. ( RVVTF ) , a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders, on Tuesday said the FDA has advised it to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.

Revive expects to submit the Type C meeting request by next week.

Revive is exploring the use of Bucillamine as a potential treatment for long COVID and is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial. It is finalizing the regulatory and clinical package that includes a proposed Phase 2 clinical study for long COVID to present to the FDA.